Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 entities : Biophytis - adr save search
Biophytis To Present Positive Results of Phase 2-3 COVA Study At ERS 2023 21st Lung Science Conference
Published: 2023-03-09 (Crawled : 10:00) - biospace.com/
BPTS | News | $0.29 -11.04% -12.41% 180K
|
Manufacturing
|
| O: 40.0%
H: 0.0%
C: -15.64%
lung conference positive results study phase 2
Biophytis Announces Promising Full Results From the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29 – October 2, 2021
Published: 2021-10-04 (Crawled : 07:00) - globenewswire.com
BPTS | News | $0.29 -11.04% -12.41% 180K
|
Manufacturing
| Email alert
Add to watchlist
phase 2 results phase 2b research trial conference
Biophytis to Present Full Results From the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29 – October 2, 2021
Published: 2021-09-29 (Crawled : 06:00) - globenewswire.com
BPTS | News | $0.29 -11.04% -12.41% 180K
|
Manufacturing
| Email alert
Add to watchlist
phase 2 results phase 2b research trial conference
Biophytis Announces DMC Second Interim Analysis Efficacy Results in the Promising Zone Allowing Continuation of Phase 2/3 COVA Study With Sarconeos (BIO101) in COVID-19
Published: 2021-09-15 (Crawled : 07:00) - globenewswire.com
BPTS | News | $0.29 -11.04% -12.41% 180K
|
Manufacturing
| Email alert
Add to watchlist
phase 2 covid phase 2/3 results
Biophytis Announces Top Line Results of SARA-INT Phase 2 Study With Sarconeos (BIO101) in Sarcopenia
Published: 2021-08-02 (Crawled : 07:00) - globenewswire.com
BPTS | News | $0.29 -11.04% -12.41% 180K
|
Manufacturing
| Email alert
Add to watchlist
topline phase 2 results
Results of Biophytis SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be Released by August 2021
Published: 2021-06-30 (Crawled : 21:00) - globenewswire.com
BPTS | News | $0.29 -11.04% -12.41% 180K
|
Manufacturing
| Email alert
Add to watchlist
phase 2 results trial
Biophytis Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milestones for the COVA Phase 2-3 Study
Published: 2021-06-30 (Crawled : 21:00) - globenewswire.com
BPTS | News | $0.29 -11.04% -12.41% 180K
|
Manufacturing
| Email alert
Add to watchlist
phase 2 covid milestone
BIOPHYTIS Completed Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim Analysis
Published: 2021-05-12 (Crawled : 06:00) - globenewswire.com
BPTS | News | $0.29 -11.04% -12.41% 180K
|
Manufacturing
| Email alert
Add to watchlist
phase 2 covid
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.